

Special Article – Spontaneous Remission

Spontaneous Remission of Cancer and Wounds Healing

Shoutko AN^{1*} and Maystrenko DN²¹Laboratory for the Cancer Treatment Methods, Saint Petersburg, Russia²Department of Vascular Surgery, Saint Petersburg, Russia

***Corresponding author:** Shoutko AN, Laboratory for the Cancer Treatment Methods, A.M. Granov Russian Research Center for Radiology and Surgical Technologies, 70 Leningradskaya str., Pesochney, St. Petersburg, Russia

Received: September 24, 2019; **Accepted:** October 25, 2019; **Published:** November 01, 2019

Abstract

The associativity of the spontaneous cancer remission with surgical trauma is considering in term of the competition of healing process outside the tumor for circulating morphogenic cells, providing proliferation in any tissues with high cells renewing, malignant preferably. The proposed competitive mechanism of Spontaneous cancer Remission phenomenon (SR) assumes the partial distraction the trophic supply from tumor to offside tissues priorities, like extremely high fetus growth, wound healing after incomplete resection, fight with infections, reparation of a multitude of non-malignant cells injured sub lethally by cytotoxic agents, and other kinds of an extra-consumption the host lymphopoietic resource mainly in the conditions of its current deficit. The definition of a reduction of tumor morphogenesis discusses as preferable instead of the activation of anticancer immunity. Pending further developments, it assumes that the nature of the SR phenomenon is similar to the rough exhaustion of lymphopoiesis at conventional cytotoxic therapy. The main task for future investigations for more reproducible SR is to elucidate of the phase of a cyclic lymphopoietic process that is optimal for surgery outside the tumor as well as for other activities, provoked morphogenesis in surrounding tissues.

Keywords: Spontaneous remission; Cancer; Surgery lymphocytes; Feeder cells; Morphogenesis; Lymphopoiesis

Abbreviation

SR: Spontaneous Remission; GR: Growth/Repair factors; HIV: Human Immunodeficiency Virus; TDT: Terminal Deoxynucleotidyl Transferase (marker of lymphoid stem cells); HSC: Hematopoietic Stem Cells; CD34: Marker of Hematopoietic Stem Cells

Introduction

An explanation of the majority of cancer problem consists of sophisticated schemes of cells immunity that are ignoring the current state of lymphopoiesis as the system at large. This trend creates many contradictions at the level of the path physiology of malignant growth and its treatment [1]. Partially, the long-term follow up studies confirm a decrease of an incidence, mortality, and prevalence of cancer in older people [2], as well as a trend toward cancer' spontaneous remission in adulthood [3] in parallel with decreasing immunity by age. However, conventional surgery, chemotherapy, radiation therapy are generally ineffective at both advanced age and advanced cancer, and these patients need some non-aggressive end-of-life care [4,5]. In this mini-review, we discuss the unclear Spontaneous Regression/Remission (SR) of cancer as a path physiological phenomenon perspective for the development of a precise therapy of cancer patients with a terminal status of health and argue new, non-immunological explanation of SR.

Two separate regenerative processes can compete for morphogenic/feeding/trophic resource of lymphopoiesis at its deficit.

Recently some authors consider cancer as a persistent wound, which provokes gene activation to heal itself via recruited circulating cells secreted the Growth/Repair factors (GR) [6,7]. Residual cancer, after surgery inside the tumor during the curable phase of the process, progresses [8,9], proving its growths analogy with wound healing.

But proposal to cure cancer with an excess of GR [7] is illogical because an excess cancer incidence and excess cancer mortality among individuals are inverse to age, being 9-4 fold higher at age 16 in comparing with advanced age 80 [10], where tissue growth near to minimal. In oppose to immune defence against cancer, conventional chemotherapy and radiation therapy are effective mostly when they provoke myelosuppression manifested by lymphocytopenia and aging of patients [1]. These data have confirmed again that the main factor of weakening of cancer activity is an age-dependent reducing both lymphopoiesis and related to it morphogenesis. Weak lymphopoiesis accompanies SR phenomenon also.

A rare (1:60000 or 1:100000) disappearance of all or at least some relevant parameters of a soundly diagnosed malignant disease without any medical treatment or "inadequate" treatment for the resulting regression is seen sporadically in every type of cancer of large volume accompanied by immune paralysis. Immunologists explain it that once, the paralyzed immune system would readjust itself and remove malignant growth. The expected spontaneous readjusting of anti-cancer immunity seems questionable at conditions of an advanced deadly disease with exhausted lymphopoiesis treated by cytotoxic agents many times already. Moreover, the SR phenomenon has multiple reasons. It notes at concomitant severe local infection with streptococci, measles, viral hepatitis, herpes zoster or chickenpox, during peritonitis, pneumonia, myocardial infarction, artificial graft versus processes, at long-term HIV-compromised T-cell immunity, and even the so-called psychoneuroimmunological reactions [11-19]. Around 40 percent of cases of SR can be related to operative trauma at the conditions of deficit of morphogenesis in the host [20]. For cases of SR is possible to see the concomitant surgical components in tissues outside of tumor such as a large resection with blood flow disorders [21], ample excision of abdominal wall, exploratory laparotomy for a

perforated ulcer with peritonitis [17], colectomy, thoracotomy, bypass surgery with intestine, bowel, hernia, followed by a second surgical exploration, postoperative fever, pneumonia, prolonged healing of postoperative wounds [22]. A SR phenomenon may be a hidden consequence of conservative surgery for histopathological estimation of normal tissue margin around the tumor in the tumor excision specimens. The volume of such conservative activity and its distance from biological margin of cancer seem crucial parameters for reliable SR provocation. They may be the reasons for often equal effectiveness of radical cancer surgery and alternative surgery in which as much as possible of a part or structure is retained [23,24]. The cases of SR noted for non-malignant diseases also [3,25]. All mentioned conditions lead to light amortization of lymphocytopoiesis of different grade.

Presently, there are no doubts that Hematopoietic Stem Cells (HSC) and young lymphocytes can promote cancer growth in their attempt to repair what they perceive as a wound or other tissue injuries including cancer itself [26]. In all such situations, the inflammatory phase of wound healing is initiated with the high infiltration of circulating morphogenic cells at the wound site, including the earliest hematopoietic progenitor $\gamma\delta$ T-cells with CD34, Terminal Deoxynucleotidyl Transferase (TDT) markers, angiogenic and regulatory lymphocytes [27-29]. Importantly, the priority in similar morphogenic service belongs to cancer as an embryonic-like tissue in organism [30]. The priority realizes typically via initial attraction the circulating morphogenic cells to the tumor from normally renewing non-malignant tissues with following body weight loss and cachexia. High resting energy expenditure in cancer patients due to both initial hyper metabolism and repeated courses of cytotoxic/ mielosuppressive treatment increase the consumption of limited morphogenesis resource first and then exhausts it faster in comparing with physiological growth only. The cachexia in cancer is a result of the gradual exhaustion of morphogenesis processes [31] that confirmed by loss of body weight and lowering of overall survival [32].

As the physiology of wound healing is similar to that of malignant tissue [6,7,33], the processes of reparation/regeneration outside the tumor could reduce its growth /aggressiveness at the conditions of deficit of lymphopoietic function. In some cases, forced regeneration of non-malignant tissues restricts the vascularisation processes in the residual tumor and results in further SR [34,35]. The survival of patients who had physical trauma after cancer diagnosis was better versus those that had physical trauma before the cancer diagnosis, showing the importance of simultaneousness separate regenerative processes for damping influencing one onto another [36]. Such type influencing is more probable at the condition of deficit of lymphopoietic activity in patients [9]. Different mechanical modulations of morphogenesis are known either for restriction of tumor development [37] or to affect the circulating lymphocytes interaction with injured non-malignant tissues [38]. According to such type of competition, even physiological proliferation at pregnancy can provoke temporary exhaustion of lymphopoiesis followed by SR as it observed for a carcinoid tumor [39]. At the late period of gestation near to delivery, the number of circulating CD34+HSC reduces significantly to half in pregnancies complicated by preeclampsia [40]. Significant long-term maternal breast cancer protection associates with only late pregnancies lasting 34 weeks or longer [41]. Thus, the SR phenomenon relates to extreme

proliferation/regeneration of large biomasses of the fetus in parallel to cancer development. In this view, any traumatic activity outside of tumor without specific cytotoxic properties can indirectly control the growth of cancer via provoking renewing processes in non-malignant tissues, such as a spontaneous engraftment of partially separated skin flaps [35]. The expected mode of tumor control in light of this could look like a crazy fantasy. For example, it could be the bone fracture followed by long-term slight mechanical stretching of the broken ends to delay the knit-like structure, as used to be done for surgical lengthening of bone with the cosmetic aim [22].

The simplest explanation of “competitive” relation of non-malignant and malignant growth processes is possible on the base of the morphogenetic function of hematopoietic stem cells and feeding lymphocytes in the condition of their deficit, but not excess. In oppose to cells immunity, the proposed competitive scheme fits at the level of physiological system the described cases of SR and some other obscure clinical phenomena such as the cases of long-term tumor dormancy, exceptional treatment-related survival after total-body irradiation of cancer patients with low, non-tumorcidal doses, as well, as results of cytotoxic chemotherapy [42], or radiation hormesis [43-45]. It seems that the benefit of such competitive kind of treatment is possible mostly at light cachexia [46] with a deficit of lymphopoiesis, but not complete exhausting of the poietic system. The data pointed on the crucial importance of the volume of injured non-malignant tissues for the successful triggering of morphogenic supply from the tumor to the newly induced injuries outside of it. Direct association between the density of lymphoid structures in tumor tissue and late recurrence after surgery [47] prove the dependence biological stage of cancer from its local growth support by feeding lymphocytes, as well as conjugacy of deep dumping of lymphopoiesis after conventional cytotoxic chemotherapy with its benefit [1,48]. However, a precise lymphopoiesis damping is harder to perform during its weakness, where the clinical practice of conventional cytotoxic therapy is not as large as for earlier stages with abundant lymphocytosis [49]. The problem is that weak lymphopoiesis at advanced cancer acts in abnormal symmetric regime with synphase fluctuations both SC production and rate of patient’s death [50,51]. It increases the risks of an overdose a weak lymphopoiesis with affected (therapeutic) factor, followed the boost of deadly exhaustion of patient’s viability. This is at least one reason for rare SR incidence. Thus, enigmatic lymphocyte aggregates in tumor and peripheral tissues, which arise in response to any form of unspecific, antigen-independent tissue injury, followed by non-resolving inflammation [52] may contribute to the non-immune pathogenic nature of SR and offer a window for further therapeutic interventions.

Conclusion

The competitive mechanism assumes the partial distraction the trophic supply from tumor to offside tissues priorities, like extremely high fetus growth, wound healing after incomplete resection, fight with infections, reparation of a multitude of non-malignant cells injured sub lethally by cytotoxic agents, and other kinds of an extra-consumption the host lymphopoietic resource mainly in the conditions of its current deficit. The definition an activation of anticancer immunity is better to replace on definition a reduction of tumor morphogenesis. Pending further developments, we assume that the nature of the SR phenomenon is similar to the rough

exhaustion of lymphopoiesis at conventional cytotoxic therapy. The main task for future investigations for more reproducible SR is to elucidate of the phase of a cyclic lymphopoietic process that is optimal for surgery outside the tumor as well as for other activities, provoked morphogenesis in surrounding tissues.

References

- Shoutko AN. Overview of Hematopoietic Stem Cells in Systemic Cancer Treatment, Aging, Pregnancy, and Radiation Hormesis Advances in Molecular Imaging. 2019; 9: 19-42.
- Harding C, Pompei F, Wilson R. Peak and Decline in Cancer at Old Ages. *Cancer*. 2012; 118: 1371-1386.
- Neven B, Magerus-Chatinet A, Florin B, Gobert D, Lambotte O, De Somer L, et al. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. *Blood*. 2011; 118: 4798-4807.
- DuMontier C, Loh KP, Bain PA, Silliman RA, Abel GA, Djulbegovic B, et al. Defining under treatment and overtreatment in older patients with cancer: A scoping review of the literature. *Journal of Clinical Oncology*. 2019; 37.
- Sineshaw HM, Jemal A, Ng K, Osarogiagbon RU, Yabroff KR, Ruddy KJ, et al. Treatment Patterns Among De Novo Metastatic Cancer Patients Who Died Within 1 Month of Diagnosis. *JNCI Cancer Spectrum*. 2019; 3.
- Meng X, Riordan N. Cancer is a Functional Repair Tissue. *Medical Hypothesis*. 2006; 66: 486-490.
- Foster DS, Jones RE, Ransom RC, Longaker MT, Norton JA. The evolving relationship of wound healing and tumor stroma *JCI Insight*. 2018; 3.
- Tohme S, Simmons RL, Tsung A. Surgery for Cancer: A Trigger for Metastases. *Cancer Res*. 2017; 77: 1548-1552.
- Alieva M, van Rheenen J, Broekman MLD. Potential impact of invasive surgical procedures on primary tumor growth and metastasis *Clinical & Experimental Metastasis*. 2018; 35: 319-331.
- Salibi PN, Agarwal V, Panczykowski DM, Puccio AM, Sheetz MA, Okonkwo DO. Lifetime Attribute Risk of Cancer from CT among Patients Surviving Severe Traumatic Brain Injury. *American Journal of Roentgenology*. 2014; 202: 397-400.
- Niakan BHB. Immune Paralysis and the Spontaneous Remission of Cancer. *Int J Cancer Clin Res*. 2017; 4: 087.
- Kuwal A, Chauhan N, Dutt N, Elhence P, Advani M, Kumar S. Spontaneous Partial Regression of a Carcinoid Tumor: Radiology May Not Capture the Real Picture. *Turk Thorac J*. 2019; 20: 153-156.
- Ooi KH, Cheo T, Ting Soon GS, Leong CN. Spontaneous regression of locally advanced nonsmall cell lung cancer *Medicine*. 2018; 97: e11291.
- Roelofsens T, Wefers C, Gorris MAJ, Textor JC, Massuger LFAG, de Vries IJM, et al. Spontaneous Regression of Ovarian Carcinoma After Septic Peritonitis; A Unique Case Report. *Frontier in oncology*. 2018; 8: 562.
- Vernon LF. William Bradley Coley, and the phenomenon of spontaneous regression. *Immunotargets and Therapy*. 2018; 7: 29-34.
- Ariza-Prota M, Martínez C, Casan P. Spontaneous regression of metastatic squamous cell lung cancer. *CLIN Case Rep*. 2018; 6: 995-998.
- Chin KM, Chan CY, Lee SY. Spontaneous regression of pancreatic cancer: A case report and literature review. *International Journal of Surgery Case Reports*. 2018; 42: 55-59.
- Dickman MJ, Bresser P, Noorduy LA, Reiss P. Spontaneous regression of Ki-positive T-cell non-Hodgkin's lymphoma in a patients with HIV-infection. *Br J Haematol*. 1992; 82: 477-478.
- Karand AB, Jaffar A, Lands RH. Spontaneous regression of acquired immune deficiency syndrome-related high grade extranodal non-Hodgkin's lymphoma. *Cancer*. 1992; 69: 1856-1857.
- Esplin N, Fergiani K, Legare TB, Stelzer JW, Bhatti H, Ali SK. Spontaneous regression of a primary squamous cell lung cancer following biopsy: a case report. *Journal of Medical Case Reports*. 2018; 12: 65.
- Mizuno T, Susa M, Horiuchi K, Shimazaki H, Nakanishi K, Chiba K. Spontaneous Regression of Myxofibrosarcoma of the Thigh after Open Biopsy *Case Rep Oncol*. 2019; 12: 364-369.
- Shoutko A, Shatinina N. Chronic Cancer - Could It Be? Coherence - International Journal of Integrated Medicine. 1998; 2: 36-40.
- Karakousis CP. Radical versus conservative cancer surgery: An anachronism? *J of Surgical Oncology*. 2001; 77: 221-224.
- Rahman GA. Breast Conserving Therapy: A surgical Technique where Little can Mean More. *J Surg Tech Case Rep*. 2011; 3: 1-4.
- Korkama ES, Armstrong AE, Jarva H, Meri S. Spontaneous Remission in Paroxysmal Nocturnal Hemoglobinuria - Return to Health or Transition Into Malignancy? *Front. Immunol*. 2018; 9: Article 1749.
- Jessy T. Immunity over inability: The spontaneous regression of cancer *J Nat Sci Biol Med*. 2011; 2: 43-49.
- Ziegler H, Welker C, Sterk M, Haarer J, Rammensee H-G, Handgretinger R, et al. Human peripheral CD4+V β 1+ $\gamma\delta$ T cells can develop into $\alpha\beta$ T cells. *Frontiers in Immunology*. 2014; 5: 645.
- Domea B, Timar J, Ladanyi A, Paku S, Renyi-Vamos F, Klepetko W, et al. Circulating Endothelial Cells, Bone Marrow-Derived Endothelial Progenitor Cells and Proangiogenic Hematopoietic Cells in Cancer: From Biology to Therapy. *Critical Reviews in Oncology/Hematology*. 2009; 69: 108-124.
- Xiong Y, Russell DL, McDonald LT, Cowart LA, LaRue AC. Hematopoietic Stem Cell-Derived Adipocytes Promote Tumor Growth and Cancer Cell Migration. *International Journal of Cancer Research and Molecular Mechanisms*. 2017; 3.
- Sonnenschein C, Soto AM, Rangarajan A, Kulkarni P. Competing views on cancer *J Biosci*. 2014; 39: 281-302.
- Vagnildhaug OM, Blum D, Wilcock A, Fayers P, Strasser F, Baracos VE, et al. The applicability of a weight loss grading system in cancer cachexia: a longitudinal analysis. *Journal of Cachexia, Sarcopenia and Muscle*. 2017; 8: 789-797.
- Vanhoutte G, van de Wiel M, Wouters K, Sels M, Bartolomeeussen L, De Keersmaecker S, et al. Cachexia in cancer: what is in the definition? *BMJ Open Gastroenterology*. 2016; 3: e000097.
- Sundaram GM, Quah S, Sampath P. Cancer: the dark side of wound healing. *The FEBS Journal*. 2018; 285: 4516-4534.
- Smith RA. Cure of lung cancer from incomplete surgical resection. *BMJ*. 1971; 2: 563-565.
- Granov AM, Shoutko AN. Paradoxes of Malignant Growth and Incompatibility of Tissues. 2002; St-Petersburg, Russia: Hippocrat. 222P.
- Delahanty DL, Marley R, Fenton A, Salvator A, Woolfer C, Erck D, et al. Comparison Between Survival from Cancer Before and After a Physical Traumatic Injury: Physical trauma Before Cancer is Associated with Decreased Survival. *Journal of Trauma Management & Outcomes*. 2015; 9: 8.
- Berrueta L, Bergholz J, Munoz D, Muskaj I, Badger GJ, Shukla A, et al. Stretching Reduces Tumor Growth in a Mouse Breast Cancer Model. *Scientific Reports*. 2018; 8: 7864.
- Morioka K, Marmor Y, Sacramento JA, Lin A, Shao T, Miclau KR, et al. Differential fracture response to traumatic brain injury suggests dominance of neuroinflammatory response in polytrauma. *Scientific Reports*. 2019; 9: 12199.
- Sewpaul A, Bargiela D, James A, Johnson SJ, French JJ. Hindawi Publishing Corporation *Case Reports in Endocrinology*. 2014; 5.
- Abdul Wahid FS, Nasaruddin MZ, Idris MRM, Tusimin M, Tumian NR, Mahdy ZA. Effects of preeclampsia on the yield of hematopoietic stem cells obtained from umbilical cord blood at delivery. *J Obstet Gynaecol Res*. 2012; 38: 490-497.

41. Husby A, Wohlfahrt J, Øyen N, Melbye M. Pregnancy duration and breast cancer risk. *Nature Communications*. 2018; 9: 1.
42. Shoutko AN, Yurkova LE, Borodulya KS, Ekimova LP. Protracted Half-Body Irradiation Instead of Chemotherapy: Life Span and Lymphocytopenia in Relapsed Ovarian Cancer. *International Journal of Tumor Therapy*. 2016; 5: 1-7.
43. Shoutko AN, Ekimova LP. Abnormal tissue proliferation and life span variability in chronically irradiated dogs. *Radiat Environ Biophys*. 2014; 53: 65-72.
44. ShoutkoAN, Ekimova LP. The Effects of Tissue Regenerative Status on Hormesis in Dogs Irradiated during Their Lifespan. *Open Journal of Biophysics*. 2017; 7: 101-115.
45. Calabrese EJ, Mattson MP. How Does Hormesis Impact Biology, Toxicology, and Medicine? *NPJ. Aging and Mechanisms of Disease*. 2017; 3.
46. De Lerma BarbaroA. The complex liaison between cachexia and tumor burden. *Oncology Reports*. 2015; 34: 1635-1649.
47. Calderaro J, Petitprez F, Becht E, Laurent A, Hirsch TZ, Rousseau B, et al. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. *J Hepatol*. 2019; 70: 58-65.
48. Common Terminology Criteria for Adverse Events (CTCAE). 2018 Protocol Development, National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD). CTCAE v5.0 Clean, Tracked, and Mapping Document (Excel) (November 27, 2017).
49. Shoutko AN, Gerasimova OA, Ekimova LP, Zherebtsov FK, Mus VF, Matyurin KS, et al. Lymphocyte Reproductive Activity Normalized to Numbers of Hematopoietic Stem Cells in Blood and Rate of Death in Fatal Diseases *International Journal of Genetics and Genomics*. 2017; 5: 54-62.
50. Shoutko A, Ekimova L, Mus V, Sokurenko V. Fluctuations of CD34 cells number in blood of cancer patients during final year of life. *Medical and Health Science Journal*. 2012; 13: 7-13.
51. Shoutko AN, Mus VF. Potential of Hematopoietic Stem Cells and Mitotic Activity in Peripheral Lymphocytes to Predict Life Expectancy of Patients with Metastatic Non-Small Cell Lung Cancer after Conventional Therapy. *Advances in Molecular Imaging (AMI)*. 2018; 8: 25-37.
52. Yin C, Mohanta S, Maffia P, Habenicht AJR. Editorial: Tertiary Lymphoid Organs (TLOs): Powerhouses of Disease Immunity. *Front. Immunol*. 2017; 8: 228.